Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Raymond James Maintains Outperform on Disc Medicine, Raises Price Target to $43

Author: Benzinga Newsdesk | May 10, 2024 01:01pm
Raymond James analyst Danielle Brill maintains Disc Medicine (NASDAQ:IRON) with a Outperform and raises the price target from $40 to $43.

Posted In: IRON